BACKGROUND/AIMS: In recent years, quality of life (QoL) assessments have proved useful for evaluating and comparing drug treatment programs. To compare QoL of patients maintained on methadone versus slow-release morphine, a prospective, randomized, double-blind, double-dummy, cross-over study was conducted. METHODS: Over two 7-week study phases, participants received either oral slow-release morphine capsules followed by methadone oral solution or vice versa. QoL status was assessed at baseline, week 7, and week 14 using the German version of the Lancashire Quality of Life Profile. RESULTS: No statistically significant difference was found between methadone and slow-release morphine in any QoL domain. A significant time effect for nearly all QoL domains was observed after 14 weeks of opioid medication, independent of the chosen drug (general well-being, p < 0.001; mental health, p = 0.001; general state of health, p = 0.018; leisure time at home, p = 0.034; leisure time out of the home, p = 0.008). Furthermore, this study revealed that even short-term maintenance yields significantly higher QoL scores in the important domain of general well-being. CONCLUSION: These results indicate that slow-release morphine has effects comparable to methadone on patient-reported QoL data and is thus a promising option for treatment of opioid-dependent subjects. (c) 2008 S. Karger AG, Basel
RCT Entities:
BACKGROUND/AIMS: In recent years, quality of life (QoL) assessments have proved useful for evaluating and comparing drug treatment programs. To compare QoL of patients maintained on methadone versus slow-release morphine, a prospective, randomized, double-blind, double-dummy, cross-over study was conducted. METHODS: Over two 7-week study phases, participants received either oral slow-release morphine capsules followed by methadone oral solution or vice versa. QoL status was assessed at baseline, week 7, and week 14 using the German version of the Lancashire Quality of Life Profile. RESULTS: No statistically significant difference was found between methadone and slow-release morphine in any QoL domain. A significant time effect for nearly all QoL domains was observed after 14 weeks of opioid medication, independent of the chosen drug (general well-being, p < 0.001; mental health, p = 0.001; general state of health, p = 0.018; leisure time at home, p = 0.034; leisure time out of the home, p = 0.008). Furthermore, this study revealed that even short-term maintenance yields significantly higher QoL scores in the important domain of general well-being. CONCLUSION: These results indicate that slow-release morphine has effects comparable to methadone on patient-reported QoL data and is thus a promising option for treatment of opioid-dependent subjects. (c) 2008 S. Karger AG, Basel
Authors: Verena E Metz; Sandra D Comer; Johanna Wuerzl; Anna Pribasnig; Gabriele Fischer Journal: Arch Womens Ment Health Date: 2014-07-15 Impact factor: 3.633
Authors: Bach Xuan Tran; Arto Ohinmaa; Anh Thuy Duong; Nhan Thi Do; Long Thanh Nguyen; Quoc Cuong Nguyen; Steve Mills; Philip Jacobs; Stan Houston Journal: Qual Life Res Date: 2011-07-06 Impact factor: 4.147
Authors: B Nosyk; J W Bray; E Wittenberg; B Aden; A A Eggman; R D Weiss; J Potter; A Ang; Y-I Hser; W Ling; B R Schackman Journal: Drug Alcohol Depend Date: 2015-10-25 Impact factor: 4.492
Authors: Hefei Wen; Janet R Cummings; Jason M Hockenberry; Laura M Gaydos; Benjamin G Druss Journal: JAMA Psychiatry Date: 2013-12 Impact factor: 21.596
Authors: Antònia Domingo-Salvany; M Teresa Brugal; Gregorio Barrio; Francisco González-Saiz; M José Bravo; Luís de la Fuente Journal: Health Qual Life Outcomes Date: 2010-12-01 Impact factor: 3.186